Home > Press > Nanotechnology drug delivery shows promise for treatment of pediatric cancer: Childhood leukemia the focus of research
Abstract:
This month, Molecular Pharmaceutics reported promising findings from the Nemours Center for Childhood Cancer Research and the Materials Science and Engineering Department at the University of Delaware, about the potential for nanotechnology to deliver chemotherapeutic agents in a way that attacks cancer cells without harming healthy cells. To date, nanoparticle-based drug delivery approaches have been poorly developed for the treatment of childhood leukemia, which comprises 30% of childhood cancers. In the Nemours study, encapsulated dexamethasone ("dex") delivered to pre-clinical models with leukemia significantly improved quality of life and survival compared to the control receiving the unencapsulated drug.
Nanotechnology drug delivery shows promise for treatment of pediatric cancer: Childhood leukemia the focus of research
Wilmington, DE | Posted on December 5th, 2012
Acute lymphoblastic leukemia (ALL) is the most common form of pediatric leukemia. Although 5-year survival rates for ALL approach 90% with available chemotherapy treatments, the deleterious side effects of the drugs, including secondary cancers and fertility, cognitive, hearing, and developmental problems, present a significant concern for survivors and their families. Dex is one of the most commonly used drugs to treat childhood leukemia and long-term systemic exposure to dex causes considerable side effects.
Studies conducted by the lead author A. K. Rajasekaran, PhD, and his team at Nemours in collaboration with Xinqiao Jia, PhD, and her team at the University of Delaware, used polymeric nanoparticles containing chemotherapeutic agents to ensure controlled delivery of drugs to cancer cells in preclinical models. "There are currently seven or eight drugs that are used for chemotherapy to treat leukemia in children," said Dr. Rajasekaran. "They are all toxic and do their job by killing rapidly dividing cells." However, he explained, these drugs don't differentiate cancer cells from other, healthy cells. "The good news is that these drugs are 80-90% effective in curing leukemia. The bad news is that many chemotherapeutic treatments cause severe side effects, especially in children." He posits that it will take researchers hundreds of millions of dollars and many years to find better alternative drug treatments. In the interim, scientists like Dr. Rajasekaran and his colleagues are working on novel ways to deliver existing and affordable drugs to children. "Our polymer synthesis and particle engineering are guided by the clinical need for reducing the side effects of cancer drugs," Dr. Jia commented. Vinu Krishnan, the first author of the study and a chemical engineer and graduate student in Materials Science and Engineering, said, "I am very excited about the results and look forward to taking this to the next level and introducing this approach for the clinical treatment of childhood leukemia". Students in Dr. Jia's group contributing to this work also include Xian Xu and Xiaowei Yang.
To date, advances in nanotechnology have been primarily concentrated around adult cancers. Nanotechnology involves the use of encapsulated particles of drugs that go into the core of the cell. The nanoparticles stick only to the cancer cells and destroy them by delivering the drug precisely, without detecting or harming the normal cells. In preclinical models of leukemia, Dr. Rajasekaran and his team were able to improve survival and quality of life via nanotechnology. Encapsulating the drug uses one third of the typical dose, with good treatment results and no discernible side effects. In addition, the mice that received the drugs delivered via nanoparticles survived longer than those that received the drug administered in the traditional way.
This work is supported by National Institutes of Health (RO1 DK56216, P20RR016458, P20 RR017716), Delaware Health Sciences Alliance, Andrew McDonough B + Foundation, Caitlin Robb Foundation, Kids Runway for Research, Sones Brothers, Nemours Foundation and funds from the University of Delaware.
####
About Nemours
The Nemours Center for Childhood Cancer Research (NCCCR) is an entity of Nemours Biomedical Research and Nemours Center for Cancer and Blood Disorders at the Alfred I. duPont Hospital for Children. The goal of the center is to evolve into a leader in research focusing on biomarkers for childhood cancers and cancers that affect families. The NCCCR works with the Christiana Care Helen F. Graham Cancer Center, the Universityof Delaware Center for Translational Research and the Delaware Biotechnology Institute. The Nemours/Alfred I. duPont Hospital for Children is a division of Nemours, which operates one of the nation's largest health systems devoted to pediatric patient care, teaching, and research. Established as The Nemours Foundation through the legacy and philanthropy of Alfred I. duPont, Nemours offers pediatric clinical care, research, education, advocacy, and prevention programs to families in the communities it serves.
For more information, please click here
Contacts:
Karen Bengston
302-298-7319
Copyright © Nemours
If you have a comment, please
Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
Bookmark:
News and information
Pioneering breakthrough of chemical nanoengineering to design drugs controlled by light June 18th, 2013
Study Shows How the Nanog Protein Promotes Growth of Head and Neck Cancer June 18th, 2013
New Method to Synthesize Zinc Oxide Nanoparticles with High Catalytic Activity June 18th, 2013
Production of Polyaniline Biosensors Modified with Conductive Polymer Composites June 18th, 2013
Govt.-Legislation/Regulation/Funding/Policy
Working backward: Computer-aided design of zeolite templates: Rice scientists apply drug-design lessons to production of industrial minerals June 17th, 2013
An Innovative material for the Green Earth: Simple and inexpensive process to make a material for CO2 adsorption June 17th, 2013
Nanoparticle Opens the Door to Clean-Energy Alternatives June 14th, 2013
Discovery of new material state counterintuitive to laws of physics June 14th, 2013
Nanomedicine
Pioneering breakthrough of chemical nanoengineering to design drugs controlled by light June 18th, 2013
Study Shows How the Nanog Protein Promotes Growth of Head and Neck Cancer June 18th, 2013
Production of Polyaniline Biosensors Modified with Conductive Polymer Composites June 18th, 2013
European Technology Platform for Nanomedicine and Nanomed2020 European Consortium Launch the Nanomedicine Award June 17th, 2013
Announcements
Pioneering breakthrough of chemical nanoengineering to design drugs controlled by light June 18th, 2013
Study Shows How the Nanog Protein Promotes Growth of Head and Neck Cancer June 18th, 2013
New Method to Synthesize Zinc Oxide Nanoparticles with High Catalytic Activity June 18th, 2013
Production of Polyaniline Biosensors Modified with Conductive Polymer Composites June 18th, 2013
Grants/Awards/Scholarships/Gifts/Contests/Honors/Records
European Technology Platform for Nanomedicine and Nanomed2020 European Consortium Launch the Nanomedicine Award June 17th, 2013
Unzipped nanotubes unlock potential for batteries: Rice University lab combines graphene nanoribbons with tin oxide for improved anodes June 13th, 2013
Ph.D. student at Hebrew University wins Kaye Award for research on delivering safer drugs through skin applications June 12th, 2013
Shape of nanoparticles points the way toward more targeted drugs: A collaboration of scientists at Sanford-Burnham and the University of California, Santa Barbara, finds that rod-shaped particles, rather than spherical particles, appear more effective at adhering to cells June 10th, 2013